Management NMIBC in COVID19 Era
We are in COVID Era and how long it will be with us is at present Unknown though there are many talks about the curve being flattened but as USI Council justifiably mention that we will be faced with limiting Urological surgeries for a sometime to come. This postponement of not offering the appropriate treatments at the initial visit of the patient could cause progression of disease but this could be more so with Urological Cancers but definitely not less with Non Urological conditions.
We had a two Webinars recently organized by USI where these aspects were discussed at some length (I am not going into details as I believe most of us would have listened to these Webinars).
The discussion that is being provided concerns ‘NMIBC Treatment in COVID19 era’.
They are discussing on management between Low Risk and High Risk NMIBC. How can they arrive at this segregation without proper evaluation including endoscopy and often TURBT? I am not in full agreement with the discussion. I would appreciate if our experts will shed light on what their preferences are in this Pandemic period.
Hoping to have a discussion on this as it is likely that this Pandemic could last longer than we predict and such issues will become of considerable importance
With warm regards,